Peter J. Schlueter, Ph.D., J.D.
Shareholder
Peter leverages his 10-year biology research career to counsel clients on intellectual property issues in biotechnology, including patent prosecution, portfolio management, and licensing. He specializes in helping early-stage companies and technology transfer offices develop strategies to maximize the value of their inventions.

Peter counsels a wide array of clients and provides the full scope of patent legal services, including freedom-to-operate and patentability analyses, non-infringement and invalidity opinions, patent preparation and prosecution, due diligence review, licensing/agreement counseling, and litigation support. The clients Peter has served over the past decade include universities, start-up ventures, established biotech companies, and investment firms.
Regardless of the type of client, Peter enjoys providing strategic legal advice to help clients maximize the scope of patent protection and ensure that every client’s IP strategy aligns with their business goals. Peter’s extensive research background and eagerness to counsel new clients gives him the unique ability to understand a wide variety of technology areas, including biochemical assays, immunotherapeutics, protein engineering, diagnostic methods, neuromodulation devices, bioelectronic detection platforms, and next generation sequencing technology.
Outside of work, Peter is an avid cyclist, enjoys any and all manner of outdoor activities, and devotes as much time and energy as possible keeping up with his two young sons.
- Shareholder, Casimir Jones S.C., 2021-present
- IP Attorney, Casimir Jones S.C., 2018-2021
- Associate IP Attorney, Michael Best & Friedrich, 2017-2018
- Associate IP Attorney, Faegre Drinker, 2014-2016
- Associate IP Attorney/Law Clerk, Patterson Thuente IP, 2012-2014
- Law Clerk, Fish & Richardson, 2011
- J.D., Mitchell Hamline 2013
- Post-Doctoral Fellowship, Chemical Biology, Harvard Medical School/MGH 2010
- Ph.D., Cellular, Molecular & Developmental Biology, University of Michigan 2006
- B.S., Biology Research/English Literature, Loras College 1999
- State Bar of Wisconsin
- State Bar of Colorado
- State Bar of Minnesota
- United States Patent and Trademark Office
- U.S. Patent No. 9,538,734 entitled, “Novel germ cell ablation compounds and uses thereof.”
- Youngnam N. Jin*, Peter J. Schlueter*, Nathalie Jurisch-Yaksi, Pui-Ying Lam, Shan Jin, Woong Y. Hwang, Jing-Ruey Joanna Yeh, Masaaki Yoshigi, Shao-En Ong, Monica Schenone, Christina R. Hartigan, Steven A. Carr & Randall T. Peterson. Noncanonical translation via deadenylated 3′ UTRs maintains primordial germ cells. Nature Chemical Biology. 2018 July; 14: 844–852. *Designates co-first authors.
- Schlueter, P. J. and Peterson, R. T. Systematizing serendipity for cardiovascular drug
discovery. Circulation. 2009 July; 120: 255-263. - Schlueter, P. J., Peng, G., Westerfield, M., Duan, C. Insulin-like growth factor signaling
regulates zebrafish embryonic growth and development by promoting cell survival and cell
cycle progression. Cell Death and Differentiation. 2007 Jun; 14(6): 1095-105. - Schlueter, P. J., Sang, X., Duan, C., Wood, A. W. Insulin-like growth factor receptor 1b is required for zebrafish primordial germ cell migration and survival. Developmental Biology.
2007 May; 305(1): 377-87. - Schlueter, P. J., Royer, T., Farah, M. H., Laser, B., Chan, S. J., Steiner, D. F., Duan, C. Gene
duplication and functional divergence of the zebrafish insulin-like growth factor 1 receptors.
FASEB Journal. 2006 Jun; 20(8): 1230-2. - Wood, A. W., Schlueter, P. J., Duan, C. Targeted knockdown of insulin-like growth factor
binding protein-2 disrupts cardiovascular development in zebrafish embryos. Molecular
Endocrinology. 2005 Apr; 19(4): 1024-34.